openPR Logo
Press release

Myelodysplastic Syndrome (MDS) Treatment Market Industry Forecast till 2025

08-14-2018 12:25 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Myelodysplastic Syndrome (MDS) Treatment Market Industry

Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8. There are various types of myelodysplastic syndrome such as refractory cytopenia with unilineage dysplasia and refractory anemia with ringed sideroblasts among others. Approved drugs for MDS include Vidaza (Azacitidine), Revlimid (Lenalidomide), Decitabine (Dacogen), and Deferasirox (Jadenu). Revlimid (Lenalidomide) patent for MDS indication will be expiring in 2023. A number of generic azacitidine-based products for MDS are launched in the global market.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/775

Rising implications associated with myelodysplastic syndrome are expected to affect the myelodysplastic syndrome treatment market

According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050. Furthermore, according to the American Society of Clinical Oncology (ASCO), age plays an important role in the occurrence of myelodysplastic syndrome as most of the people diagnosed with the disease are of age 65 and older. These factors are expected to boost the myelodysplastic syndrome treatment.

The global myelodysplastic syndrome treatment market was valued at US$ 2,213.2 million in 2017 and is expected to witness a CAGR of 12.7% during the forecast period (2017 – 2025).

Endeavor to introduce highly effective therapies for various MDS types would support the market growth

Major pharmaceutical organizations such as Celgene are investing major amounts in research and development of MDS specific drugs and many of their drugs are showing potential in the clinical trials as shown in the table no.1. Furthermore, in 2016, Opsona Therapeutics Ltd. received orphan drug designation for its OPN-305 humanized IgG4 monoclonal antibody for MDS treatment. Also, after Celgene lost its U.S. exclusivity for Vidaza, many generic formulations have entered in the market for Vidaza and Natco Pharma is also expected to launch generic version of Vidaza in 2017, which will further boost myelodysplastic syndrome treatment market.

Increasing knowledge about the disease and its symptoms with advanced methods and techniques for early diagnosis and treatment for various forms of the disease is fuelling the market growth. The American Cancer Society estimates that, about 1/3rd of the MDS patients can rapidly advance to cancer of bone marrow cells called as acute myeloid leukemia.

Awareness initiatives to lead to early diagnosis and treatment

Furthermore, governmental organizations and drug manufacturing companies are spreading awareness about the disease with various ways, such as by providing funding and conducting awareness programs. MDS International Foundation is one such organization which is supporting the patients through various ways be it treatment or psychological support. Furthermore EvansMDS a funding initiative of the Edward P.Evans Foundation has awarded $45 Mn since 2011 for research specifically focused on MDS and AML.

Ask for customization @ https://www.coherentmarketinsights.com/insight/request-customization/775

Key players operating in the myelodysplastic syndrome treatment market include Celgene, Novartis, and Otsuka. Some of the other market players are Astellas, Astex, Acceleron Pharma, Onconova Pharmaceuticals, GlaxoSmithKline, Eli-Lilly, and CTI Biopharma.

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Myelodysplastic Syndrome (MDS) Treatment Market Industry Forecast till 2025 here

News-ID: 1179226 • Views:

More Releases from Coherent Market Insights

Meal Replacement Market Market to Hit $22.01 Bn by 2032 with a CAGR of 5.8% |Abbott Laboratories, Amway, Atkins, Blue Diamond Growers
Meal Replacement Market Market to Hit $22.01 Bn by 2032 with a CAGR of 5.8% |Abb …
The Meal Replacement Market is estimated to be valued at USD 14.82 Bn in 2025 and is expected to reach USD 22.01 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Meal Replacement Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key growth
Deep Cycle Battery Market, Market Outlook : Projected to Exceed USD 4.73 Billion by 2032 with a 7.9% CAGR |C&D Technologies Inc., Crown Battery Manufacturing Co., East Penn Manufacturing Co. Inc., EnerSys
Deep Cycle Battery Market, Market Outlook : Projected to Exceed USD 4.73 Billion …
The deep cycle battery market is estimated to be valued at USD 2.77 billion in 2025 and is expected to reach USD 4.73 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Deep Cycle Battery Market, Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business
Consumer Electronics Packaging Market Market Projected to Witness Huge Growth by 2025-2032 |Hangzhou Xunda Packaging Co., Smurfit Kappa Group PLC, DS Smith Plc, Pregis Corporation
Consumer Electronics Packaging Market Market Projected to Witness Huge Growth by …
The consumer electronics packaging market is estimated to be valued at USD 26.57 Bn in 2025 and is expected to reach USD 81.72 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 17.4% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Consumer Electronics Packaging Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends,
Ceramic Armor Market Market Set to Witness Significant Growth by 2025-2032 |Koninklijke DSM N.V., BAE Systems, Morgan Advanced Materials , Saint-Gobain S.A.
Ceramic Armor Market Market Set to Witness Significant Growth by 2025-2032 |Koni …
The global ceramic armor market is estimated to be valued at USD 2.75 Bn in 2025 and is expected to reach USD 4.08 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Ceramic Armor Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends,

All 5 Releases


More Releases for MDS

Prominent Myelodysplastic Syndrome (MDS) Drugs Market Trend for 2025: Innovative …
What Are the Projected Growth and Market Size Trends for the Myelodysplastic Syndrome (MDS) Drugs Market? The myelodysplastic syndrome (MDS) drugs market has expanded steadily in recent years. It is projected to increase from $3.47 billion in 2024 to $3.73 billion in 2025, reflecting a CAGR of 7.5%. The past growth can be attributed to the aging population, advancements in targeted therapies, ongoing clinical trials, and increased awareness. The myelodysplastic syndrome (MDS)
Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast to 2031
"Myelodysplastic Syndrome (MDS) Treatment Market 2024," The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Myelodysplastic Syndrome (MDS) Treatment market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Myelodysplastic Syndrome (MDS) Treatment industry, providing stakeholders
MDS Dental Assisting Academy Brings Flexible Dental Assisting Courses Online
CONTACT: MDS Dental Assisting Academy Address: 122 Thicket Lane City: Freedom State: California Postcode: 95019 Country: USA Telephone: 1-888-637-4732 Website: https://dentalassistanceschool.com/ Email: info@mds4rda.com California, January 28th, 2022: Are you interested in dentistry? What do you think of a career in dental assisting? If being a dental assistant is your career choice, then an RDA program in MDS Dental Assisting Academy will suit you the best. They provide an interactive course
CASwell Secures Products Against MDS Attacks
New firmware updates for network devices & servers against ZombieLoad, RIDL & Fallout Taipei, Taiwan - August 27th, 2019 - CASwell Inc., a leading manufacturer of innovative and high-performance server solutions for SD-WAN (uCPE/vCPE) and network security systems, announced today that most of its network devices and servers have received updates for their firmware or BIOS making them secure against any malicious attacks based on MDS vulnerabilities. With these updates customers
Myeloidysplastic Syndromes (MDS) – Epidemiology Insights (2016-2028)
Myeloidysplastic syndromes (MDS) can be described as a group of hematologic malignancies, that occurr due to abnormality in blood-forming cells in the bone marrow. It is a rare blood cancer and can be mild, moderate or severe, in terms of severity. Download the sample report @ https://www.pharmaproff.com/request-sample/1162 This syndrome can be classified into three main types: MDS with single lineage dysplasia wherein a single type of blood cell appears abnormal; multilineage
e-MDs Enhances Customer Satisfaction with U.S. Based IT Support
AUSTIN, TEXAS -- (AUGUST 8, 2011) – e-MDs, a leading provider of electronic health record (EHR) and practice management solutions, recently described one of the key elements of award-winning customer service they offer their clients: U.S. based software support and services. Recent studies conducted by Claes Fornell International Group, an organization that measures customer satisfaction, indicate that offshore call centers can cause high levels of frustration. To enhance customer support